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Abstract
The  presence  of  activating  mutations  in  the  EGFR  gene  influences  cell  proliferation,
angiogenesis,  and increases metastatic ability; it  has a significant impact on the choice of
medical  therapy of  non-small  cell  lung cancer  (NSCLC).  The use of  targeted therapy with
tyrosine kinase inhibitors requires performance of appropriate genetic tests. The aim of this
study was to design a real-time PCR-based diagnostic kit for fast and cheap of EGFR mutations
testing in paraffin blocks and plasma, and kit  validation using samples from patients with
NSCLC, and also comparative estimation of diagnostic features of real-time PCR with wild type
blocking and digital PCR for mutation testing in blood plasma. The study included 156 patients
with various types of adenocarcinoma differentiation. It was designed a simple and efficient
real-time PCR-based method of detecting L858R activating mutation and del19 deletion in the
EGFR gene for DNA isolated from paraffin blocks. Kit for EGFR mutations was validated using
411 samples of paraffin blocks. The proposed system showed high efficiency for DNA testing
from paraffin blocks: a concordance with results of testing with therascreen® EGFR RGQ PCR Kit
("Qiagen", Germany) was 100%. It has been shown the possibility of using this test system for
the detection of mutations in plasma.
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